Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein C receptors (EPCR)

Patent metadata

Field	Value
Publication number	US-9808505-B2
Application number	US-201414765922-A
Country	US
Kind code	B2
Filing date	Mar 10, 2014
Priority date	Mar 8, 2013
Publication date	Nov 7, 2017
Grant date	Nov 7, 2017

Abstract

The influence of TF, endothelial cell protein C receptor (EPCR) and protease activated receptor-1 (PAR1) on tumor growth of malignant pleural mesothelioma (MPM) is disclosed. MPM cells that lack or express TF, EPCR or PAR1 and a murine orthotopic model of MPM led to the discovery that intrapleural administration into nude mice of REN MPM cells expressing TF and PAR1 but lacking EPCR and PAR2 generated large pleural cavity tumors. Suppression of TF or PAR1 expression markedly reduced tumor growth. Overexpression of TF in non-aggressive MPM cells expressing EPCR and PAR1 but exhibiting minimal levels of TF failed to alter their tumorigenicity. Introduction of EPCR expression in aggressive MPM cells attenuated tumor growth whereas EPCR silencing in non-aggressive MPM cells overexpressing TF increased tumorigenicity of non-aggressive cells. Expression of EPCR by MPM cells suppresses tumor growth and treats MPM.

First claim

What is claimed is:

1. A method of sensitizing malignant pleural mesothelioma (MPM) cells to killing by endogenous cytokines in a subject in need thereof, said method comprising transducing MPM cells to express Endothelial Protein C Receptor (EPCR), by exposing them to a nucleic acid expression vector, wherein said vector is administered intrapleurally to said subject, the vector comprising a nucleotide sequence comprising:
(i) an EPCR-coding sequence consisting of the nucleotide of SEQ ID NO:1 encoding the EPCR of SEQ ID NO:2, said nucleic acid EPCR-coding sequence operably linked to a promoter to express said EPCR-coding sequence in MPM cells, and said nucleic acid EPCR-coding sequence optionally linked to
(ii) an enhancer and/or other expression control element for expression of EPCR in the MPM cells,
wherein cells so transduced and expressing EPCR are sensitized to killing by endogenous cytokines interferon-γ (IFNγ) and tumor necrosis factor-α (TNFα) compared to MPM cells not so transduced that are not so sensitized to such killing.

2. A method of killing sensitized MPM cells which have been sensitized according to the method of claim 1 , said method comprising exposing said transduced MPM cells to an effective amount of intrapleurally administered:
(i) IFNγ which acts in combination with endogenous TNFα in such killing, or
(ii) combination of IFNγ and TNFα which together kill said sensitized MPM cells.

3. The method of claim 1 wherein the promoter is:
(a) CREBBP/EP300 inhibitory protein-1 gene promoter; or
(b) mesothelin gene promoter further linked to a mesothelin gene enhancer element.

Assignees

• Univ Texas

Inventors

• Pendurthi Usha R
• Lella Vijaya M R
• Gaddam Shivakeshava
• Idell Steven

Classifications

• A61K38/217

  IFN-gamma · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• A61K38/177 Primary

  Receptors; Cell surface antigens; Cell surface determinants · CPC title

• C12N2710/10371

  Demonstrated in vivo effect · CPC title